Microbes in the treatment of Diabetes and its complications

Suneeta Narumanchi, Yashavanthi Mysore, P. A. Nidhina Haridas

Forskningsoutput: Kapitel i bok/rapport/konferenshandlingKapitelVetenskapligPeer review


Diabetes mellitus is a metabolic disease affecting millions of people worldwide. Hyperglycemia is the hallmark of all kind of diabetes including Type 1, 2 and gestational diabetes. Long term hyperglycemia can lead to macrovascular and microvascular complications such as cardiovascular diseases, renal disorders, neuropathic disorders like diabetic foot ulcers and retinopathy. This can be prevented by altering the lifestyle and by using therapeutic agents. These therapeutic agents are either chemically or biologically synthesized or obtained from natural sources like plants or microbes. Recent studies have shown that gut microbiota has a role in development of metabolic diseases. Also many new strategies have been suggested, using probiotics or microbial formulations to treat such diseases. There are several secondary metabolites currently in use for the treatments of diabetes and its complications and many small molecules have been identified which are potential therapeutics. In this chapter, we discuss about microbes, microbial products and genetically engineered microbes and its mechanisms for the treatment of diabetes and its comorbidities.
Titel på värdpublikationMicrobial Biotechnology
RedaktörerJ. Patra , G. Das, HS. Shin
Antal sidor11
FörlagSpringer Singapore
Utgivningsdatum15 feb. 2018
ISBN (tryckt)978-981-10-7139-3
ISBN (elektroniskt)978-981-10-7140-9
StatusPublicerad - 15 feb. 2018
MoE-publikationstypA3 Del av bok eller annan forskningsbok

Bibliografisk information



  • 3111 Biomedicinska vetenskaper

Citera det här